Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 14/20 | 0.74 |
| ▸ | RXRB | P28702 | 11/20 | 0.74 |
| ▸ | RXRG | P48443 | 7/20 | 0.74 |
| ▸ | RARB | P10826 | 9/20 | 0.64 |
| ▸ | RARG | P13631 | 8/20 | 0.64 |
| ▸ | CYP26A1 | O43174 | 3/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.61 |
| ▸ | CYP26B1 | Q9NR63 | 2/20 | 0.61 |
| ▸ | RARA | P10276 | 6/20 | 0.61 |
| ▸ | CRABP2 | P29373 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9165893 | 0.91 | RXRA (0.69) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL9175054 | 0.87 | RXRA (0.60) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL9595211 | 0.85 | RARB (0.60) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL7720657 | 0.85 | RXRA (1.00) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL9551786 | 0.85 | RARB (0.63) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL7876431 | 0.83 | RXRA (0.67) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL9250190 | 0.83 | RXRA (0.59) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL9189346 | 0.83 | RARB (0.60) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL9698293 | 0.83 | RXRA (0.66) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL8839146 | 0.82 | RXRA (0.67) | RXRARXRBRXRGRARBRARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0642499-A1 | RETINOIDS AND THEIR USE IN TREATING SKIN DISEASES AND LEUKEMIA | PFIZER INC. (US) | 1995-03-15 | — | — | EP | claimed |
| WO-1993006086-A1 | RETINOIDS AND THEIR USE IN TREATING SKIN DISEASES AND LEUKEMIA | PFIZER INC. (US) | 1993-04-01 | — | — | WO | claimed |
| US-8633335-B2 | Retinoid prodrug compound | Research Founation Itsuu Laboratory (JP) | 2014-01-21 | — | — | US | disclosed |
| US-8633335-B2 | Retinoid prodrug compound | Research Founation Itsuu Laboratory (JP) | 2014-01-21 | — | — | US | disclosed |
| US-20100286427-A1 | RETINOID PRODRUG COMPOUND | RESEARCH FOUNDATION ITSUU LABORATORY (JP) | 2010-11-11 | — | — | US | disclosed |
| US-20100286427-A1 | RETINOID PRODRUG COMPOUND | RESEARCH FOUNDATION ITSUU LABORATORY (JP) | 2010-11-11 | — | — | US | disclosed |
| US-5231113-A | Skin disorders, immunology or wound healing agents | ALLERGAN, INC. (US) | 1993-07-27 | — | — | US | disclosed |
| WO-1993006086-A1 | RETINOIDS AND THEIR USE IN TREATING SKIN DISEASES AND LEUKEMIA | PFIZER INC. (US) | 1993-04-01 | — | — | WO | disclosed |
| EP-0337689-B1 | TETRALIN ESTERS OF PHENOLS OR BENZOIC ACIDS HAVING RETINOID LIKE ACTIVITY | ALLERGAN, INC (US) | 1993-03-10 | — | — | EP | disclosed |
| US-5130335-A | Treatment of skin disorders | ALLERGAN, INC. (US) | 1992-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286427-A1 | RETINOID PRODRUG COMPOUND | STRA6, RXRA, RXRB | RXRA 2/4885RXRB 3/4885RXRG 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.